Brucellosis Vaccines Market, by Type (RB51 Vaccine, S19 Vaccine, B19 Vaccine and Others (45/20 vaccine, SR82 vaccine, etc.)), by Application (Cattle, Sheep, Goat and Others (swine, horses, etc.)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
Brucellosis is an infectious disease caused by bacteria. Animals that are most commonly infected include sheep, cattle, goats, pigs, and dogs, among others. These disease can also occur in humans when they are in contact with infected animals or animal products contaminated with bacteria.
Moreover, RB51 Vaccine, S19 Vaccine, B19 Vaccine and Others (45/20 vaccine, SR82 vaccine, etc.) are the type of vaccine used for the brucellosis in animals.
Furthermore, increasing launches of brucellosis vaccination programmes is expected to drive the market growth over the forecast period.
In August 2021, brucella vaccination program was launched at Thoubal, Manipur, India for the control and eradication of brucellosis in female calves of 4-8 months age group.
Market Dynamics
Increasing prevalence of brucellosis is expected to drive the global brucellosis vaccines market growth over the forecast period. For instance, according to an article published by the National Center for Biotechnology Information, a series of databases relevant to biotechnology and biomedicine, brucellosis is the world’s most widespread zoonotic disease, a type of disease that passes from an animal to a human. The source stated that there are a reported 500,000 cases of human brucellosis each year, globally. However, true incidence is estimated to be 5,000,000 to 12,500,000 cases each year, globally.
According to the same source, brucellosis is recognized as the world’s most common laboratory-acquired infection.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook